Trial Profile
A phase II study of Palonosetron combined with Dexamethasone and Aprepitant to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy for esophageal cancer.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Palonosetron (Primary) ; Aprepitant; Aprepitant; Dexamethasone
- Indications Chemotherapy-induced nausea and vomiting
- Focus Therapeutic Use
- 14 Feb 2011 New trial record